Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;27(3):245-254.
doi: 10.1080/13697137.2024.2334083. Epub 2024 Apr 15.

Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis

Matheus Pedrotti Chavez  1 , Eric Pasqualotto  1 , Rafael Oliva Morgado Ferreira  1 , Alexandre Hohl  2 , Francisco Cezar Aquino de Moraes  3 , Pedro Henrique Siedschlag Schmidt  1 , Anna Luíza Soares de Oliveira Rodrigues  4 , Joao Roberto de Sa  5
Affiliations
Review

Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis

Matheus Pedrotti Chavez et al. Climacteric. 2024 Jun.

Abstract

This systematic review and meta-analysis investigated the efficacy and safety of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. PubMed, Cochrane Library, Embase and Web of Science were searched for randomized controlled trials (RCTs) published from inception to June 2023, comparing fezolinetant to placebo in postmenopausal women suffering from moderate-to-severe VMS. The mean difference and risk ratio were calculated for continuous and binary outcomes, respectively. R software was used for the statistical analysis, and RoB-2 (Cochrane) to assess the risk of bias. We performed subgroup analysis based on different dosing regimens. Five RCTs comprising 3302 patients were included. Compared with placebo, at 12-week follow-up, fezolinetant significantly reduced the daily frequency of moderate-to-severe VMS (weighted mean difference [WMD] - 2.36; 95% confidence interval [CI] - 2.92, -1.81) and daily severity of moderate-to-severe VMS (WMD -0.22; 95% CI -0.31, -0.13). Also, fezolinetant significantly improved the quality of life (WMD -0.42; 95% CI -0.58, -0.26) and sleep disturbance (WMD -1.10; 95% CI -1.96, -0.24). There were no significant differences between groups in adverse events. These findings support the efficacy and safety of fezolinetant for the treatment of VMS related to menopause.

Keywords: Fezolinetant; menopause vasomotor symptoms; neurokinin 3 receptor antagonist; non-hormonal; sleep disorder.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

LinkOut - more resources